HIF1A and B-cell chronic lymphocytic leukemia: From the literature, HIF-1α seems to be an interesting new target for CLL therapy, as it regulates the interaction of CLL cells with the TME and is upregulated in unmutated immunoglobulin heavy-chain variable region genes (IGHV) and TP53-disrupted CLL patients [26,27].